Understand ALS treatment options: An evidence-based overview of current care

Understand ALS treatment options by separating therapies that may modestly slow disease progression from supportive measures designed to preserve breathing, nutrition, communication, mobility, comfort, and quality of life. ALS has no cure, and treatment planning must be individualized with an ALS neurologist and a multidisciplinary care team. 1

What ALS treatment is designed to achieve

ALS progressively damages motor neurons that control voluntary movement. Weakness can affect the limbs, torso, throat, speech muscles, and breathing muscles, while thinking and memory are usually preserved. Because the disease can progress differently between individuals, care generally combines disease-modifying medication with symptom management, rehabilitation, assistive equipment, and planning for changing respiratory, swallowing, and communication needs. 2

Current treatment cannot reverse motor-neuron degeneration after it occurs. The principal goals are to slow progression where possible, reduce complications, maintain independence for as long as practical, and support informed decisions about future care. Merck Manual describes treatment as supportive, while clinical reviews characterize available disease-modifying medicines as having limited or modest effects rather than curative results. 13

Medicines that may modify disease progression

Riluzole is an FDA-approved oral medicine and was the first approved ALS treatment in the United States. It is thought to reduce harmful glutamate signaling and may modestly slow progression or extend survival for some people. Treatment can involve oral tablets or liquid formulations, with prescribing decisions based on the patient’s clinical situation, other medicines, and monitoring requirements. 4

Edaravone is another FDA-approved treatment and is available in intravenous and oral suspension formulations. Evidence indicates that it may slow functional decline in eligible patients, but its suitability depends on clinical assessment, treatment schedule, tolerability, and regulatory labeling. These medicines do not restore lost strength, and their expected benefit must be weighed against adverse effects, administration demands, and ongoing follow-up. 5

Genetic eligibility and tofersen

Tofersen, marketed as Qalsody, is an antisense oligonucleotide approved for adults with ALS associated with a confirmed mutation in the SOD1 gene. This makes genetic testing potentially relevant for treatment discussions, particularly when a clinician suspects familial ALS or when personal and family history indicates a possible inherited form. Most ALS cases are sporadic, but inherited cases represent an important subgroup. 67

Tofersen is not a general treatment for every person with ALS. Eligibility requires confirmation of the relevant SOD1 mutation, and administration and monitoring occur under specialist supervision. The FDA granted accelerated approval for this rare genetic form of ALS, meaning continued evidence collection remains part of regulatory oversight. Genetic counseling can help explain test results, family implications, and the limits of genetic information. 8

Breathing and swallowing support

Respiratory weakness is a major area of ALS management. Noninvasive ventilation, such as BiPAP, can assist breathing when respiratory muscles weaken and may improve quality of life and survival. Respiratory assessments are repeated as the condition changes, because symptoms can develop gradually and some people may not recognize reduced breathing capacity without clinical testing. 9

Swallowing difficulty can cause inadequate nutrition, dehydration, choking, or aspiration. A feeding tube may help maintain nutrition, hydration, and medication delivery when swallowing becomes unsafe or insufficient. Decisions about timing require discussion with neurology, nutrition, speech-language, and procedural teams, because the balance between respiratory status, goals of care, daily burden, and expected benefit varies among individuals. 10

Rehabilitation, mobility, and communication

Physical and occupational therapy can address mobility, transfers, positioning, fatigue management, and adaptations for daily activities. Speech-language therapy evaluates speech and swallowing, while nutrition professionals help address changing calorie, hydration, and texture needs. Multidisciplinary ALS clinics commonly coordinate neurologists, pulmonologists, rehabilitation specialists, speech-language pathologists, dietitians, and social workers so that separate problems are managed as one evolving care plan. 11

Communication support becomes increasingly important when speech or hand control declines. Speech-generating devices, alternative access methods, and eye-tracking systems can help people communicate when conventional typing or speaking becomes difficult. Assistive mobility devices can similarly preserve participation and reduce fall risk. Equipment selection should reflect current ability, anticipated progression, home layout, caregiver capacity, and insurance or funding rules. 12

Clinical trials and practical treatment decisions

Clinical trials remain an important option because researchers are studying gene-targeted therapies, stem-cell approaches, immune treatments, devices, and other disease-modifying strategies. A trial may involve strict inclusion criteria, travel, repeated testing, placebo or comparison groups, uncertain benefit, and potential risks. ClinicalTrials.gov provides a registry of recruiting and completed ALS studies, but eligibility must be confirmed by the study team. 13

Treatment decisions should account for diagnosis, disease subtype, genetic findings, respiratory measurements, swallowing function, medication tolerance, communication needs, and personal goals. Palliative care can be integrated alongside disease-directed treatment to address discomfort, emotional concerns, caregiver strain, and advance-care planning. Ongoing maintenance is substantial because equipment, medication schedules, nutrition plans, and respiratory support may need repeated adjustment as function changes. 14

Risks, limits, and questions for the care team

Every treatment has limitations. Disease-modifying medicines offer modest benefits for many patients, genetic therapies apply only to defined populations, and supportive devices require fitting, training, maintenance, and reassessment. Clinical reviews also emphasize that the ALS treatment field remains challenging, with emerging approaches requiring stronger evidence before their safety and effectiveness can be established. 3

Useful clinical questions include whether genetic testing is appropriate, how respiratory function is being monitored, when swallowing assessment is needed, which therapies may support communication, and what side effects or follow-up tests are expected. Decisions should be made with licensed clinicians rather than based on unverified supplements, experimental claims, or assumptions that a treatment appropriate for one ALS subtype applies to everyone. 6

Sources

1. Merck Manual Professional Edition, “Amyotrophic Lateral Sclerosis (ALS) and Other Motor Neuron Diseases”
2. Harvard Health, “Amyotrophic Lateral Sclerosis (ALS)”
3. Frontiers in Neurology, “Current and emerging therapeutic strategies for amyotrophic lateral sclerosis”
4. ALS News Today, “Amyotrophic Lateral Sclerosis (ALS) Treatment”
5. U.S. Food and Drug Administration, “FDA Approves New Treatment for ALS”
6. National Institute of Neurological Disorders and Stroke, “Amyotrophic Lateral Sclerosis (ALS)”
7. The ALS Association, “How to Treat ALS”
8. U.S. Food and Drug Administration, “FDA Grants Accelerated Approval to Treatment for Rare Form of ALS”
9. Cleveland Clinic, “Amyotrophic Lateral Sclerosis (ALS)”
10. Mayo Clinic, “Amyotrophic Lateral Sclerosis: Diagnosis and Treatment”
11. Muscular Dystrophy Association, “Medical Management of ALS”
12. MedlinePlus, “Amyotrophic Lateral Sclerosis”
13. ClinicalTrials.gov, “Amyotrophic Lateral Sclerosis Studies”
14. National Health Service, “Motor Neurone Disease: Treatment”